Cell Differentiation Trajectory Predicts Prognosis and Immunotherapeutic Response in Clear Cell Renal Cell Carcinoma

Clear cell renal cell carcinoma (ccRCC) is the main type of malignancy in kidney related to glucose metabolism. Primary single cell culture and single cell sequencing are novel research technologies. In this study, we explored the differentiation status of ccRCC cells and its significance in prognos...

Full description

Saved in:
Bibliographic Details
Main Authors: Jin Xu, Xi Chen, Yinyu Chen, Qiushuang Wang, Yingliang Jin, Huashuo Zhao
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Genetics Research
Online Access:http://dx.doi.org/10.1155/2022/8422339
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832551079392313344
author Jin Xu
Xi Chen
Yinyu Chen
Qiushuang Wang
Yingliang Jin
Huashuo Zhao
author_facet Jin Xu
Xi Chen
Yinyu Chen
Qiushuang Wang
Yingliang Jin
Huashuo Zhao
author_sort Jin Xu
collection DOAJ
description Clear cell renal cell carcinoma (ccRCC) is the main type of malignancy in kidney related to glucose metabolism. Primary single cell culture and single cell sequencing are novel research technologies. In this study, we explored the differentiation status of ccRCC cells and its significance in prognosis and immunotherapeutic response through bioinformatics. We characterized distinct differentiation states and differentiation-related genes (DRGs) in ccRCC cells through single cell RNA sequencing (scRNA-seq) analysis. Combined with bulk RNA-seq data, we classified patients into two clusters and found that this classification was closely correlated with patient prognosis and immunotherapeutic responses. Based on machine learning, we identified a prognostic risk model composed of 14 DRGs, including BTG2, CDKN1A, COL6A1, CPM, CYB5D2, FOSB, ID2, ISG15, PLCG2, SECISBP2, SOCS3, TES, ZBTB16, and ZNF704, to predict the survival rate of patients and then constructed a nomogram model integrating clinicopathological characteristics and risk score for clinical practice. In the study of immune checkpoints, we found that patients in the high-risk group had a disposition to get worse prognosis and better effects of immune checkpoint blocking therapies. Finally, we found the expression level of model DRGs was associated with a tumor-immune microenvironment (TIME) pattern and the response of 83 compounds or inhibitors was significantly different in the two risk groups. In a word, our study highlights the potential contribution of cell differentiation in prognosis judgment and immunotherapy response and offers promising therapeutic options for ccRCC patients.
format Article
id doaj-art-ca0a4aea50cf401994d75bd658ee1c20
institution Kabale University
issn 1469-5073
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Genetics Research
spelling doaj-art-ca0a4aea50cf401994d75bd658ee1c202025-02-03T06:05:01ZengWileyGenetics Research1469-50732022-01-01202210.1155/2022/8422339Cell Differentiation Trajectory Predicts Prognosis and Immunotherapeutic Response in Clear Cell Renal Cell CarcinomaJin Xu0Xi Chen1Yinyu Chen2Qiushuang Wang3Yingliang Jin4Huashuo Zhao5Department of BiostatisticsDepartment of BiostatisticsSchool of StomatologyDepartment of BiostatisticsDepartment of BiostatisticsDepartment of BiostatisticsClear cell renal cell carcinoma (ccRCC) is the main type of malignancy in kidney related to glucose metabolism. Primary single cell culture and single cell sequencing are novel research technologies. In this study, we explored the differentiation status of ccRCC cells and its significance in prognosis and immunotherapeutic response through bioinformatics. We characterized distinct differentiation states and differentiation-related genes (DRGs) in ccRCC cells through single cell RNA sequencing (scRNA-seq) analysis. Combined with bulk RNA-seq data, we classified patients into two clusters and found that this classification was closely correlated with patient prognosis and immunotherapeutic responses. Based on machine learning, we identified a prognostic risk model composed of 14 DRGs, including BTG2, CDKN1A, COL6A1, CPM, CYB5D2, FOSB, ID2, ISG15, PLCG2, SECISBP2, SOCS3, TES, ZBTB16, and ZNF704, to predict the survival rate of patients and then constructed a nomogram model integrating clinicopathological characteristics and risk score for clinical practice. In the study of immune checkpoints, we found that patients in the high-risk group had a disposition to get worse prognosis and better effects of immune checkpoint blocking therapies. Finally, we found the expression level of model DRGs was associated with a tumor-immune microenvironment (TIME) pattern and the response of 83 compounds or inhibitors was significantly different in the two risk groups. In a word, our study highlights the potential contribution of cell differentiation in prognosis judgment and immunotherapy response and offers promising therapeutic options for ccRCC patients.http://dx.doi.org/10.1155/2022/8422339
spellingShingle Jin Xu
Xi Chen
Yinyu Chen
Qiushuang Wang
Yingliang Jin
Huashuo Zhao
Cell Differentiation Trajectory Predicts Prognosis and Immunotherapeutic Response in Clear Cell Renal Cell Carcinoma
Genetics Research
title Cell Differentiation Trajectory Predicts Prognosis and Immunotherapeutic Response in Clear Cell Renal Cell Carcinoma
title_full Cell Differentiation Trajectory Predicts Prognosis and Immunotherapeutic Response in Clear Cell Renal Cell Carcinoma
title_fullStr Cell Differentiation Trajectory Predicts Prognosis and Immunotherapeutic Response in Clear Cell Renal Cell Carcinoma
title_full_unstemmed Cell Differentiation Trajectory Predicts Prognosis and Immunotherapeutic Response in Clear Cell Renal Cell Carcinoma
title_short Cell Differentiation Trajectory Predicts Prognosis and Immunotherapeutic Response in Clear Cell Renal Cell Carcinoma
title_sort cell differentiation trajectory predicts prognosis and immunotherapeutic response in clear cell renal cell carcinoma
url http://dx.doi.org/10.1155/2022/8422339
work_keys_str_mv AT jinxu celldifferentiationtrajectorypredictsprognosisandimmunotherapeuticresponseinclearcellrenalcellcarcinoma
AT xichen celldifferentiationtrajectorypredictsprognosisandimmunotherapeuticresponseinclearcellrenalcellcarcinoma
AT yinyuchen celldifferentiationtrajectorypredictsprognosisandimmunotherapeuticresponseinclearcellrenalcellcarcinoma
AT qiushuangwang celldifferentiationtrajectorypredictsprognosisandimmunotherapeuticresponseinclearcellrenalcellcarcinoma
AT yingliangjin celldifferentiationtrajectorypredictsprognosisandimmunotherapeuticresponseinclearcellrenalcellcarcinoma
AT huashuozhao celldifferentiationtrajectorypredictsprognosisandimmunotherapeuticresponseinclearcellrenalcellcarcinoma